Middle East and Africa Antimicrobial Susceptibility Testing Market - Indsutry Trends and Forecast to 2028

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 65
1.1 OBJECTIVES OF THE STUDY 65
1.2 MARKET DEFINITION 65
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 65
1.4 LIMITATIONS 67
1.5 MARKETS COVERED 67
2 MARKET SEGMENTATION 70
2.1 MARKETS COVERED 70
2.2 GEOGRAPHICAL SCOPE 71
2.3 YEARS CONSIDERED FOR THE STUDY 72
2.4 CURRENCY AND PRICING 72
2.5 DBMR TRIPOD DATA VALIDATION MODEL 73
2.6 MULTIVARIATE MODELLING 76
2.7 PRODUCT TYPE LIFELINE CURVE 77
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 78
2.9 DBMR MARKET POSITION GRID 79
2.10 MARKET APPLICATION COVERAGE GRID 80
2.11 VENDOR SHARE ANALYSIS 81
2.12 SECONDARY SOURCES 82
2.13 ASSUMPTIONS 82
3 EXECUTIVE SUMMARY 83
4 PREMIUM INSIGHTS 85
5 MARKET OVERVIEW 86
5.1 DRIVERS 88
5.1.1 RISING EPIDEMIC AND PANDEMIC OUTBREAK 88
5.1.2 GROWING HEALTHCARE EXPENDITURE 88
5.1.3 INCREASING MIDDLE EAST AND AFRICA PREVALENCE OF INFECTIOUS DISEASES 89
5.1.4 INCREASING PREVALENCE OF MULTI-DRUG RESISTANCE ORGANISM 89
5.1.5 GROWING INFRASTRUCTURE FACILITIES 89
5.1.6 HIGHER ADOPTION OF TECHNOLOGICALLY ADVANCED SUSCEPTIBILITY TESTING METHODS 90

5.2 RESTRAINTS 90
5.2.1 STRINGENT GOVERNMENT REGULATIONS 90
5.2.2 HIGH COSTS 91
5.2.3 SHORTAGE OF SKILLED PERSONNEL 91
5.3 OPPORTUNITIES 92
5.3.1 TECHNOLOGICAL ADVANCEMENTS 92
5.3.2 INVESTMENTS IN HEALTHCARE INFRASTRUCTURE 92
5.3.3 INFRASTRUCTURE OF NEW GENOMIC IDENTIFICATION METHODS 93
5.3.4 INCREASE IN FUNDING 93
5.4 CHALLENGES 94
5.4.1 EMERGENCE OF LOCAL PLAYER IN THE MARKETS 94
5.4.2 LACK OF CLINICAL DATA FROM FDA 94
5.4.3 DELAYS BETWEEN CLINICAL BREAKPOINT AND ITS CLEARANCE 94
6 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 95
6.1 IMPACT ON PRICE 95
6.2 IMPACT ON DEMAND 95
6.3 IMPACT ON SUPPLY 95
6.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19 96
6.5 CONCLUSION: 96
7 MIDDLE EAST AND AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE 97
7.1 OVERVIEW 98
7.2 INSTRUMENTS 101
7.2.1 MANUAL 102
7.2.1.1 MINIATURIZED IDENTIFICATION SYSTEMS 102
7.2.1.2 SUSCEPTIBILITY TESTING DISCS 102
7.2.1.2.1 HEXA DISCS 103
7.2.1.2.1.1 GRAM NEGATIVE ORGANISM 103
7.2.1.2.1.2 GRAM POSITIVE ORGANISM 104
7.2.1.2.1.3 GENERAL PURPOSE 104
7.2.1.2.1.4 ANAEROBIC BACTERIA 104
7.2.1.2.1.5 ANTIFUNGAL 104
7.2.1.2.1.6 OTHERS 104

7.2.1.2.2 OCTA DISCS 104
7.2.1.2.2.1 GRAM NEGATIVE ORGANISM 105
7.2.1.2.2.2 GRAM POSITIVE ORGANISM 105
7.2.1.2.2.3 UTI ORGANISMS 105
7.2.1.2.2.4 PSEUDOMONAS 105
7.2.1.2.2.5 GENERAL PURPOSE 105
7.2.1.2.3 DODECA DISCS 106
7.2.1.2.3.1 GENERAL PURPOSE 106
7.2.1.2.3.2 GRAM NEGATIVE ORGANISM 106
7.2.1.2.3.3 GRAM POSITIVE ORGANISM 106
7.2.1.2.3.4 PSEUDOMONAS 106
7.2.1.2.3.5 UTI ORGANISMS 107
7.2.1.2.4 ICOSA DISCS 107
7.2.1.2.4.1 GENERAL PURPOSE 107
7.2.1.2.4.2 PSEUDOMONAS 107
7.2.1.2.4.3 UTI ORGANISMS 107
7.2.1.3 MIC STRIPS 107
7.2.1.3.1 COMBINATION ANTIBACTERIAL 108
7.2.1.3.2 DUAL ANTIBACTERIAL 108
7.2.1.3.3 MULTIPLE ANTIBACTERIAL 108
7.2.1.3.4 SINGLE ANTIBACTERIAL 108
7.2.1.3.5 ANTIFUNGAL 108
7.2.2 AUTOMATED IDENTIFICATION AND SUSCEPTIBILITY TESTING SYSTEM 108
7.3 CONSUMABLES & ACCESSORIES 109
7.3.1 REAGENT AND BROTHS 110
7.3.2 MEDIA 110
7.3.3 SUSCEPTIBILITY PANELS 110
7.3.4 OTHERS 110
7.4 SERVICES & SOFTWARE 110
8 MIDDLE EAST AND AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,BY METHOD 112
8.1 OVERVIEW 113
8.2 DISK DIFFUSION 116
8.3 DILUTION 116
8.4 MASS SPECTROMETRY METHOD 117
8.5 E-TESTS 117
8.6 GENOTYPIC METHODS 118
8.7 OTHERS 119

9 MIDDLE EAST AND AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE 120
9.1 OVERVIEW 121
9.2 ANTIBACTERIAL TESTING 124
9.3 ANTIFUNGAL TESTING 124
9.4 OTHERS 125
10 MIDDLE EAST AND AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION 126
10.1 OVERVIEW 127
10.2 CLINICAL DIAGNOSTICS 130
10.3 DRUG DISCOVERY AND DEVELOPMENT 131
10.4 EPIDEMIOLOGY 131
10.5 OTHERS 132
11 MIDDLE EAST AND AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER 134
11.1 OVERVIEW 135
11.2 HOSPITALS 138
11.3 DIAGNOSTIC LABORATORIES 139
11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 140
11.5 CONTRACT RESEARCH ORGANISATION 140
11.6 RESEARCH CENTRES & ACADEMIC INSTITUTES 142
11.7 OTHERS 142
12 MIDDLE EAST AND AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY DISTRIBUTION CHANNEL 145
12.1 OVERVIEW 146
12.2 DIRECT SALES 149
12.3 RETAIL SALES 150
12.4 THIRD PARTY DISTRIBUTOR 150

13 MIDDLE EAST AND AFRICA ANTIMICROBIAL SUCEPTIBILITY TESTING MARKET BY GEOGRAPHY 152
13.1 OVERVIEW 152
13.2 MIDDLE EAST AND AFRICA 156
13.2.1 SOUTH AFRICA 165
13.2.2 SAUDI ARABIA 170
13.2.3 UAE 175
13.2.4 EGPYPT 180
13.2.5 ISRAEL 185
13.2.6 REST OF MIDDLE EAST AND AFRICA 190
14 MIDDLE EAST AND AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: COMPANY LANDSCAPE 191
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 191
15 SWOT 192
16 COMPANY PROFILE 193
16.1 THERMO FISHER SCIENTIFIC INC. 193
16.1.1 COMPANY SNAPSHOT 193
16.1.2 REVENUE ANALYSIS 193
16.1.3 COMPANY SHARE ANALYSIS 194
16.1.4 PRODUCT PORTFOLIO 194
16.1.5 RECENT DEVELOPMENTS 195
16.2 BIOMRIEUX SA 196
16.2.1 COMPANY SNAPSHOT 196
16.2.2 REVENUE ANALYSIS 196
16.2.3 COMPANY SHARE ANALYSIS 197
16.2.4 PRODUCT PORTFOLIO 197
16.2.5 RECENT DEVELOPMENTS 197
16.3 DANAHER 199
16.3.1 COMPANY SNAPSHOT 199
16.3.2 REVENUE ANALYSIS 199
16.3.3 COMPANY SHARE ANALYSIS 200
16.3.4 PRODUCT PORTFOLIO 200
16.3.5 RECENT DEVELOPMENTS 201

16.4 MERCK KGAA 203
16.4.1 COMPANY SNAPSHOT 203
16.4.2 REVENUE ANALYSIS 203
16.4.3 COMPANY SHARE ANALYSIS 204
16.4.4 PRODUCT PORTFOLIO 204
16.4.5 RECENT DEVELOPMENTS 204
16.5 ACCELERATE DIAGNOSTICS, INC. 206
16.5.1 COMPANY SNAPSHOT 206
16.5.2 REVENUE ANALYSIS 206
16.5.3 PRODUCT PORTFOLIO 207
16.5.4 RECENT DEVELOPMENTS 207
16.6 ALIFAX S.R.L. 208
16.6.1 COMPANY SNAPSHOT 208
16.6.2 PRODUCT PORTFOLIO 208
16.6.3 RECENT DEVELOPMENTS 209
16.7 BACTERIOSCAN, INC. 210
16.7.1 COMPANY SNAPSHOT 210
16.7.2 PRODUCT PORTFOLIO 210
16.7.3 RECENT DEVELOPMENTS 210
16.8 BD 212
16.8.1 COMPANY SNAPSHOT 212
16.8.2 REVENUE ANALYSIS 212
16.8.3 PRODUCT PORTFOLIO 213
16.8.4 RECENT DEVELOPMENTS 213
16.9 BIO-RAD LABORATORIES, INC. 215
16.9.1 COMPANY SNAPSHOT 215
16.9.2 REVENUE ANALYSIS 215
16.9.3 PRODUCT PORTFOLIO 216
16.9.4 RECENT DEVELOPMENTS 216
16.10 CREATIVE DIAGNOSTICS 217
16.10.1 COMPANY SNAPSHOT 217
16.10.2 PRODUCT PORTFOLIO 217
16.10.3 RECENT DEVELOPMENTS 217
16.11 ERBA GROUP 219
16.11.1 COMPANY SNAPSHOT 219
16.11.2 PRODUCT PORTFOLIO 219
16.11.3 RECENT DEVELOPMENTS 219

16.12 GENEFLUIDICS, INC. 221
16.12.1 COMPANY SNAPSHOT 221
16.12.2 PRODUCT PORTFOLIO 221
16.12.3 RECENT DEVELOPMENTS 221
16.13 HIMEDIA LABORATORIES 223
16.13.1 COMPANY SNAPSHOT 223
16.13.2 PRODUCT PORTFOLIO 223
16.13.3 RECENT DEVELOPMENTS 223
16.14 LIOFILCHEM S.R.L. 225
16.14.1 COMPANY SNAPSHOT 225
16.14.2 PRODUCT PORTFOLIO 225
16.14.3 RECENT DEVELOPMENTS 225
16.15 MAST GROUP LTD. 227
16.15.1 COMPANY SNAPSHOT 227
16.15.2 PRODUCT PORTFOLIO 227
16.15.3 RECENT DEVELOPMENTS 227
16.16 MERLIN GESELLSCHAFT FUR MICROBIOLOGISCHE DIAGNOSTIKA MBH 229
16.16.1 COMPANY SNAPSHOT 229
16.16.2 PRODUCT PORTFOLIO 229
16.16.3 RECENT DEVELOPMENTS 229
16.17 NUMEDII, INC. 231
16.17.1 COMPANY SNAPSHOT 231
16.17.2 TECHNOLOGY PORTFOLIO 231
16.17.3 RECENT DEVELOPMENTS 231
16.18 ROSCO DIAGNOSTICA A/S 233
16.18.1 COMPANY SNAPSHOT 233
16.18.2 PRODUCT PORTFOLIO 233
16.18.3 RECENT DEVELOPMENT 233
16.19 SYNBIOSIS 234
16.19.1 COMPANY SNAPSHOT 234
16.19.2 PRODUCT PORTFOLIO 234
16.19.3 RECENT DEVELOPMENTS 234
16.20 ZHUHAI DL BIOTECH CO., LTD 236
16.20.1 COMPANY SNAPSHOT 236
16.20.2 PRODUCT PORTFOLIO 236
16.20.3 RECENT DEVELOPMENT 236
17 QUESTIONNAIRE 237
18 RELATED REPORTS 240